Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Yang, Liu ^a   Guo, Geng ^a   Niu, Xiao Yuan ^a   Liu, Jing ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GLIOBLASTOMA ASSOCIATED ANTIGEN; GLIOBLASTOMA SPECIFIC ANTIGEN; GLIOMA STEM CELL ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DENDRITIC CELL; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; BRAIN NEOPLASMS; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; PHYSIOLOGY;

ANIMALS; BRAIN NEOPLASMS; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL;

EID: 84934301377     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/717530     Document Type: Review

References (117)

1. P. Y. Wen and S. Kesari, "Malignant gliomas in adults", New England Journal of Medicine, vol. 359, no. 5, pp. 492-507, 2008.
2. I. Jovcevska, N. Kocevar, and R. Komel, "Glioma and glioblastoma-how much do we (not) know?" Molecular Clinical Oncology, vol. 1, no. 6, pp. 935-941, 2013.
3. Y. Mineharu, M. G. Castro, P. R. Lowenstein, N. Sakai, and S. Miyamoto, "Dendritic Cell-based Immunotherapy for glioma: multiple regimens and implications in clinical trials", Neurologia Medico-Chirurgica, vol. 53, no. 11, pp. 741-754, 2013.
4. M. L. Gruber and W. P. Buster, "Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma", American Journal of Clinical Oncology, vol. 27, no. 1, pp. 33-38, 2004.
5. M.-Y. Yang, P. M. Zetler, R. M. Prins, H. Khan-Farooqi, and L. M. Liau, "Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications", Expert Review of Neurotherapeutics, vol. 6, no. 10, pp. 1481-1494, 2006.
6. M. A. Cheever and C. S. Higano, "PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine", Clinical Cancer Research, vol. 17, no. 11, pp. 3520-3526, 2011.
7. K. Traynor, "Ipilimumab approved for metastatic melanoma", The American Journal of Health-System Pharmacy, vol. 68, no. 9, p. 768, 2011.
8. A. Bregy, T. M. Wong, A. H. Shah, J. M. Goldberg, and R. J. Komotar, "Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme", Cancer Treatment Reviews, vol. 39, no. 8, pp. 891-907, 2013.
9. J. C. Marsh, J. Goldfarb, T. D. Shafman, and A. Z. Diaz, "Current status of immunotherapy and gene therapy for high-grade gliomas", Cancer Control, vol. 20, no. 1, pp. 43-48, 2013.
10. L. H. Butterfield, "Dendritic cells in cancer immunotherapy clinical trials: are we making progress?" Frontiers in Immunology, vol. 4, article 454, 2013.
11. E. S. Trombetta and I. Mellman, "Cell biology of antigen processing in vitro and in vivo", Annual Review of Immunology, vol. 23, pp. 975-1028, 2005.
12. L. Cohn and L. Delamarre, "Dendritic cell-targeted vaccines", Frontiers in Immunology, vol. 5, article 255, 2014.
13. X. Jie, L. Hua, W. Jiang, F. Feng, G. Feng, and Z. Hua, "Clinical application of a dendritic cell vaccine raised against heatshocked glioblastoma", Cell Biochemistry and Biophysics, vol. 62, no. 1, pp. 91-99, 2012.
14. G. Napolitani, A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia, "Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells", Nature Immunology, vol. 6, no. 8, pp. 769-776, 2005.
15. M. Fujita, X. Zhu, R. Ueda et al., "Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10", Cancer Research, vol. 69, no. 4, pp. 1587-1595, 2009.
16. R. B. Mailliard, A. Wankowicz-Kalinska, Q. Cai et al., "Alphatype-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity", Cancer Research, vol. 64, no. 17, pp. 5934-5937, 2004.
17. P. Parajuli, R. L. Mosley, V. Pisarev et al., "Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets", Experimental Hematology, vol. 29, no. 10, pp. 1185-1193, 2001.
18. B. J. Weigel, N. Nath, P. A. Taylor et al., "Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses", Blood, vol. 100, no. 12, pp. 4169-4176, 2002.
19. P. A. Cohen, G. K. Koski, B. J. Czerniecki et al., "STAT3-And STAT5-dependent pathways competitively regulate the pan-differentiation of CD34 pos cells into tumor-competent dendritic cells", Blood, vol. 112, no. 5, pp. 1832-1843, 2008.
20. + T-cell cross-priming but is ineffective as a therapy", Cancer Research, vol. 66, no. 9, pp. 4895-4903, 2006.
21. A. Iellem, M. Mariani, R. Lang et al., "Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4 (+) CD25 (+) regulatory T cells", The Journal of Experimental Medicine, vol. 194, no. 6, pp. 847-853, 2001.
22. D. Capece, D. Verzella, M. Fischietti, F. Zazzeroni, and E. Alesse, "Targeting costimulatory molecules to improve antitumor immunity", Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 926321, 17 pages, 2012.
23. K. J. Lafferty, H. S. Warren, and J. A. Woolnough, "A mediator acting as a costimulator for the development of cytotoxic responses in vitro", Advances in Experimental Medicine and Biology, vol. 114, pp. 497-501, 1979.
24. Y. Mineharu, G. D. King, A. G. Muhammad et al., "Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design", Clinical Cancer Research, vol. 17, no. 14, pp. 4705-4718, 2011.
25. G. Driessens, J. Kline, and T. F. Gajewski, "Costimulatory and coinhibitory receptors in anti-tumor immunity", Immunological Reviews, vol. 229, no. 1, pp. 126-144, 2009.
26. + T regulatory cells: implications and impact on tumor-mediated immune suppression", Journal of Immunology, vol. 180, no. 5, pp. 2967-2980, 2008.
27. R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, "The B7 family revisited", Annual Review of Immunology, vol. 23, pp. 515-548, 2005.
28. G. L. Sica, I. H. Choi, G. Zhu et al., "B7-H4, a molecule of the B7 family, negatively regulates T cell immunity", Immunity, vol. 18, no. 6, pp. 849-861, 2003.
29. M. L. Del Rio, C. L. Lucas, L. Buhler, G. Rayat, and J. I. Rodriguez-Barbosa, "HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation", Journal of Leukocyte Biology, vol. 87, no. 2, pp. 223-235, 2010.
30. T. H. Watts, "TNF/TNFR family members in costimulation of T cell responses", Annual Review of Immunology, vol. 23, pp. 23-68, 2005.
31. M. Croft, "Costimulation of T cells by OX40, 4-1BB, and CD27", Cytokine and Growth Factor Reviews, vol. 14, no. 3-4, pp. 265-273, 2003.
32. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., "Improved survival with ipilimumab in patients with metastatic melanoma", The New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.
33. + T cell tolerance", The Journal of Experimental Medicine, vol. 196, no. 12, pp. 1627-1638, 2002.
34. S. N. Lim, S. Kuhn, E. Hyde, and F. Ronchese, "Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy", Journal of Immunotherapy, vol. 35, no. 9, pp. 670-679, 2012.
35. R. M. Prins, N. Craft, K. W. Bruhn et al., "The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity", Journal of Immunology, vol. 176, no. 1, pp. 157-164, 2006.
36. O. M. Grauer, J. W. Molling, E. Bennink et al., "TLR ligands in the local treatment of established intracerebral murine gliomas", Journal of Immunology, vol. 181, no. 10, pp. 6720-6729, 2008.
37. G. W. Stone, S. Barzee, V. Snarsky et al., "Nanoparticle-delivered multimeric soluble CD40L DNA combined with toll-like receptor agonists as a treatment for melanoma", PLoS ONE, vol. 4, no. 10, Article ID e7334, 2009.
38. F. Calabi, J. M. Jarvis, L. Martin, and C. Milstein, "Two classes of CD1 genes", European Journal of Immunology, vol. 19, no. 2, pp. 285-292, 1989.
39. M. K. Hunn and I. F. Hermans, "Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines", OncoImmunology, vol. 2, no. 4, Article ID e23789, 2013.
40. Y. Latchman, C. R. Wood, T. Chernova et al, "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", Nature Immunology, vol. 2, no. 3, pp. 261-268, 2001.
41. J. A. Brown, D. M. Dorfman, F.-R. Ma et al., "Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production", The Journal of Immunology, vol. 170, no. 3, pp. 1257-1266, 2003.
42. D. L. Boone, E. E. Turer, E. G. Lee et al., "The ubiquitinmodifying enzyme A20 is required for termination of Toll-like receptor responses", Nature Immunology, vol. 5, no. 10, pp. 1052-1060, 2004.
43. J. E. Boudreau, A. Bonehill, K. Thielemans, and Y. Wan, "Engineering dendritic cells to enhance cancer immunotherapy", Molecular Therapy, vol. 19, no. 5, pp. 841-853, 2011.
44. + T cells and dendritic cells enhances cytokine production", The Journal of Immunology, vol. 177, no. 2, pp. 885-895, 2006.
45. J.-H. Gu and G. Li, "Dendritic cell-based immunotherapy for malignant glioma", Neuroscience Bulletin, vol. 24, no. 1, pp. 39-44, 2008.
46. S. Phuphanich, C. J. Wheeler, J. D. Rudnick et al., "Phase i trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma", Cancer Immunology, Immunotherapy, vol. 62, no. 1, pp. 125-135, 2013.
47. ∗0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain", Clinical Cancer Research, vol. 8, no. 9, pp. 2851-2855, 2002.
48. M. Hatano, J. Eguchi, T. Tatsumi et al., "EphA2 as a glioma-associated antigen: a novel target for glioma vaccines", Neoplasia, vol. 7, no. 8, pp. 717-722, 2005.
49. S. Saikali, T. Avril, B. Collet et al., "Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy", Journal of Neuro-Oncology, vol. 81, no. 2, pp. 139-148, 2007.
50. N. Brösicke, F. K. H. Van Landeghem, B. Scheffler, and A. Faissner, "Tenascin-C is expressed by human glioma in vivo and shows a strong association with tumor blood vessels", Cell and Tissue Research, vol. 354, no. 2, pp. 409-430, 2013.
51. H. Guo, Y. Wang, T. Song et al., "Silencing of survivin using YM155 inhibits invasion and suppresses proliferation in glioma cells", Cell Biochemistry and Biophysics, 2014.
52. G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu, "HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells", Cancer Research, vol. 64, no. 14, pp. 4980-4986, 2004.
53. C. L. Nutt, R. A. Betensky, M. A. Brower, T. T. Batchelor, D. N. Louis, and A. O. Stemmer-Rachamimov, "YKL-40 is a differential diagnostic marker for histologic subtypes of highgrade gliomas", Clinical Cancer Research, vol. 11, no. 6, pp. 2258-2264, 2005.
54. Y. Chiba, M. Kinoshita, Y. Okita et al., "Use of 11C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma", Journal of Neurosurgery, vol. 116, no. 4, pp. 835-842, 2012.
55. D. A. Reardon, K. W. Wucherpfennig, G. Freeman et al., "An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma", Expert Review of Vaccines, vol. 12, no. 6, pp. 597-615, 2013.
56. X. Xu, F. Stockhammer, and M. Schmitt, "Cellular-based immunotherapies for patients with glioblastoma multiforme", Clinical and Developmental Immunology, vol. 2012, Article ID 764213, 15 pages, 2012.
57. A. J. Wong, J. M. Ruppert, S. H. Bigner et al., "Structural alterations of the epidermal growth factor receptor gene in human gliomas", Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 7, pp. 2965-2969, 1992.
58. J. H. Sampson, A. B. Heimberger, G. E. Archer et al., "Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma", Journal of Clinical Oncology, vol. 28, no. 31, pp. 4722-4729, 2010.
59. J. L. Lasky III, E. H. Panosyan, A. Plant et al., "Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas", Anticancer Research, vol. 33, no. 5, pp. 2047-2056, 2013.
60. K. Dziurzynski, S. M. Chang, A. B. Heimberger et al., "Consensus on the role of human cytomegalovirus in glioblastoma", Neuro-Oncology, vol. 14, no. 3, pp. 246-255, 2012.
61. R. M. Prins, X. Wang, H. Soto et al., "Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients", Journal of Immunotherapy, vol. 36, no. 2, pp. 152-157, 2013.
62. M. A. Neller, J. A. López, and C. W. Schmidt, "Antigens for cancer immunotherapy", Seminars in Immunology, vol. 20, no. 5, pp. 286-295, 2008.
63. S. Nava, M. Dossena, S. Pogliani et al., "An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma", PLoS ONE, vol. 7, no. 12, Article ID e52301, 2012.
64. M. Eyrich, J. Rachor, S. C. Schreiber, M. Wolfl, and P. G. Schlegel, "Dendritic cell vaccination in pediatric Gliomas: lessons learnt and future perspectives", Frontiers in Pediatrics, vol. 1, article 12, 2013.
65. + T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma", The Journal of Immunology, vol. 173, no. 7, pp. 4352-4359, 2004.
66. Y. Li, L.-X. Wang, G. Yang, F. Hao, W. J. Urba, and H.-M. Hu, "Efficient cross-presentation depends on autophagy in tumor cells", Cancer Research, vol. 68, no. 17, pp. 6889-6895, 2008.
67. J. Thorburn, H. Horita, J. Redzic, K. Hansen, A. E. Frankel, and A. Thorburn, "Autophagy regulates selective HMGB1 release in tumor cells that are destined to die", Cell Death and Differentiation, vol. 16, no. 1, pp. 175-183, 2009.
68. L. Prestegarden and P. Ø. Enger, "Cancer stem cells in the central nervous system-a critical review", Cancer Research, vol. 70, no. 21, pp. 8255-8258, 2010.
69. S. Pellegatta, P. L. Poliani, D. Corno et al., "Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas", Cancer Research, vol. 66, no. 21, pp. 10247-10252, 2006.
70. X. Jin, J.-E. Jung, S. Beck, and H. Kim, "Cell surface Nestin is a biomarker for glioma stem cells", Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 496-501, 2013.
71. S. K. Singh, I. D. Clarke, T. Hide, and P. B. Dirks, "Cancer stem cells in nervous system tumors", Oncogene, vol. 23, no. 43, pp. 7267-7273, 2004.
72. S. Kasper, "Exploring the origins of the normal prostate and prostate cancer stem cell", Stem Cell Reviews, vol. 4, no. 3, pp. 193-201, 2008.
73. A. Bentivegna, D. Conconi, E. Panzeri et al., "Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples", Cancer Science, vol. 101, no. 2, pp. 416-424, 2010.
74. K. Okuno, S. Ohta, H. Kato, T. Taga, K. Sugita, and Y. Takeuchi, "Expression of neural stem cell markers in malignant rhabdoid tumor cell lines", Oncology Reports, vol. 23, no. 2, pp. 485-492, 2010.
75. A. Jimeno, G. Feldmann, A. Suárez-Gauthier et al., "A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development", Molecular Cancer Therapeutics, vol. 8, no. 2, pp. 310-314, 2009.
76. D. Corbeil, K. Röper, A. Hellwig et al., "The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions", The Journal of Biological Chemistry, vol. 275, no. 8, pp. 5512-5520, 2000.
77. A. Wu, J. Wei, L.-Y. Kong et al., "Glioma cancer stem cells induce immunosuppressive macrophages/microglia", Neuro-Oncology, vol. 12, no. 11, pp. 1113-1125, 2010.
78. T. Di Tomaso, S. Mazzoleni, E. Wang et al., "Immunobiological characterization of cancer stem cells isolated from glioblastoma patients", Clinical Cancer Research, vol. 16, no. 3, pp. 800-813, 2010.
79. S. Bao, Q. Wu, R. E. McLendon et al., "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response", Nature, vol. 444, no. 7120, pp. 756-760, 2006.
80. A.-M. Bleau, D. Hambardzumyan, T. Ozawa et al., "PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells", Cell Stem Cell, vol. 4, no. 3, pp. 226-235, 2009.
81. Q. Xu, G. Liu, X. Yuan et al., "Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens", Stem Cells, vol. 27, no. 8, pp. 1734-1740, 2009.
82. A. J. Ghods, D. Irvin, G. Liu et al., "Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells", Stem Cells, vol. 25, no. 7, pp. 1645-1653, 2007.
83. B. Ji, Q. Chen, B. Liu et al., "Glioma stem cell-targeted dendritic cells as a tumor vaccine against malignant glioma", Yo n s e i Medical Journal, vol. 54, no. 1, pp. 92-100, 2013.
84. M. A. Hatiboglu, J. Wei, A. S. G. Wu, and A. B. Heimberger, "Immune therapeutic targeting of glioma cancer stem cells", Targeted Oncology, vol. 5, no. 3, pp. 217-227, 2010.
85. P. Kalinski, Y. Nakamura, P. Watchmaker, A. Giermasz, R. Muthuswamy, and R. B. Mailliard, "Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines", Immunologic Research, vol. 36, no. 1-3, pp. 137-146, 2006.
86. S. Koido, Y. Enomoto, V. Apostolopoulos, and J. Gong, "Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines", Anticancer Research, vol. 34, no. 8, pp. 3917-3924, 2014.
87. J. A. Wargo, L. Y. Schumacher, B. Comin-Anduix et al., "Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells", Cancer Gene Therapy, vol. 12, no. 6, pp. 516-527, 2005.
88. R. M. Prins, C. J. Shu, C. G. Radu et al., "Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain", Cancer Immunology, Immunotherapy, vol. 57, no. 9, pp. 1279-1289, 2008.
89. Y. Mineharu, A. G. Muhammad, K. Yagiz et al., "Gene therapymediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-kappaB signaling improves the efficacy of immunotherapy in a brain cancer model", Neurotherapeutics, vol. 9, no. 4, pp. 827-843, 2012.
90. J. N. Ihle and I. M. Kerr, "Jaks and Stats in signaling by the cytokine receptor superfamily", Trends in Genetics, vol. 11, no. 2, pp. 69-74, 1995.
91. + T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients", Journal for ImmunoTherapy of Cancer, vol. 2, article 10, 2014.
92. R. Moriggl, D. J. Topham, S. Teglund et al., "Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells", Immunity, vol. 10, no. 2, pp. 249-259, 1999.
93. + T cells in a melanoma model", Journal of Immunology, vol. 186, no. 9, pp. 5068-5077, 2011.
94. S. Akira, "Functional roles of STAT family proteins: lessons from knockout mice", Stem Cells, vol. 17, no. 3, pp. 138-146, 1999.
95. O. Insug, G. Ku, H. C. J. Ertl, and M. Blaszczyk-Turin, "A dendritic cell vaccine induces protective immunity to intracranial growth of glioma", Anticancer Research, vol. 22, no. 2A, pp. 613-621, 2002.
96. R. Saito, M. Mizuno, N. Nakahara et al., "Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-β gene therapy for malignant glioma in an experimental mouse intracranial glioma", International Journal of Cancer, vol. 111, no. 5, pp. 777-782, 2004.
97. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma", Journal of Clinical Oncology, vol. 29, no. 3, pp. 330-336, 2011.
98. C. Siepl, S. Bodmer, K. Frei et al., "The glioblastoma-derived T cell suppressor factor/transforming growth factor-β2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor", European Journal of Immunology, vol. 18, no. 4, pp. 593-600, 1988.
99. W. Maes, G. G. Rosas, B. Verbinnen et al., "DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma", Neuro-Oncology, vol. 11, no. 5, pp. 529-542, 2009.
100. H. Trachtman, F. C. Fervenza, D. S. Gipson et al., "A phase 1, single-dose study of fresolimumab, an anti-TGF-α antibody, in treatment-resistant primary focal segmental glomerulosclerosis", Kidney International, vol. 79, no. 11, pp. 1236-1243, 2011.
101. U. Bogdahn, P. Hau, G. Stockhammer et al., "Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study", Neuro-Oncology, vol. 13, no. 1, pp. 132-142, 2011.
102. + T-cells are controlled by multiple pathways at multiple levels", International Reviews of Immunology, vol. 26, no. 3-4, pp. 145-160, 2007.
103. O. M. Grauer, S. Nierkens, E. Bennink et al., "CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglionia immune responses in vivo", International Journal of Cancer, vol. 121, no. 1, pp. 95-105, 2007.
104. O. M. Grauer, R. P. M. Sutmuller, W. Van Maren et al., "Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model", International Journal of Cancer, vol. 122, no. 8, pp. 1794-1802, 2008.
105. M. A. Morse, A. C. Hobeika, T. Osada et al., "Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines", Blood, vol. 112, no. 3, pp. 610-618, 2008.
106. A. A. Thomas, M. S. Ernstoff, and C. E. Fadul, "Immunotherapy for the treatment of glioblastoma", Cancer Journal, vol. 18, no. 1, pp. 59-68, 2012.
107. D. A. Mitchell, X. Cui, R. J. Schmittling et al., "Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans", Blood, vol. 118, no. 11, pp. 3003-3012, 2011.
108. J. F. Curtin, M. Candolfi, T. M. Fakhouri et al., "Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials", PLoS ONE, vol. 3, no. 4, Article ID e1983, 2008.
109. E. Bettelli, M. Dastrange, and M. Oukka, "Foxp3 interacts with nuclear factor of activated T cells and NF-kappaB to repress cytokine gene expression and effector functions of T helper cells", Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 14, pp. 5138-5143, 2005.
110. J. H. Park, J. S. Ko, Y. Shin et al., "Intranuclear interactomic inhibition of FoxP3 suppresses functions of Treg cells", Biochemical and Biophysical Research Communications, vol. 452, no. 1, pp. 1-7, 2014.
111. J. C. Rodrigues, G. C. Gonzalez, L. Zhang et al., "Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties", Neuro-Oncology, vol. 12, no. 4, pp. 351-365, 2010.
112. B. Raychaudhuri, P. R. J. Ireland, J. Ko et al., "Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma", Neuro-Oncology, vol. 13, no. 6, pp. 591-599, 2011.
113. H. Zhang, M. Tian, C. Xiu, Y. Wang, and G. Tang, "Enhancement of antitumor activity by combination of tumor lysatepulsed dendritic cells and celecoxib in a rat glioma model", Oncology Research, vol. 20, no. 10, pp. 447-455, 2013.
114. M. Fujita, G. Kohanbash, W. Fellows-Mayle et al., "COX-2 blockade suppresses gliomagenesis by inhibiting myeloidderived suppressor cells", Cancer Research, vol. 71, no. 7, pp. 2664-2674, 2011.
115. D. A. Reardon, S. Turner, K. B. Peters et al., "A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma", Journal of the National Comprehensive Cancer Network, vol. 9, no. 4, pp. 414-427, 2011.
116. W. Kim and L. M. Liau, "Dendritic cell vaccines for brain tumors", Neurosurgery Clinics of North America, vol. 21, no. 1, pp. 139-157, 2010.
117. K. L. Knutson and M. L. Disis, "Tumor antigen-specific T helper cells in cancer immunity and immunotherapy", Cancer Immunology, Immunotherapy, vol. 54, no. 8, pp. 721-728, 2005.